Close Menu

University of British Columbia

Research groups and companies are developing and applying tools to enrich for and capture CTCs to diagnose tumors early and monitor patients during treatment.

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.

A team led by the University of British Columbia homed in on a variant that linked to increased liver enzyme levels and liver injury during interferon-β treatment.

Choice of Identity

Sociologists report that people select what aspects of their genetic ancestry test results they incorporate into their sense of ethnic or racial identity.

In PNAS this week: alternative splicing patterns in sunflowers, EGFR inhibitor resistance in lung adenocarcinoma, and more.

In Cell this week: interactions between malignant and immune cells in ovarian cancer, gene regulatory features in mouse macrophages, and more.

The method uses hydrogel encapsulation, which mimics a tissue sample, in order to allow circulating tumor cell isolation and extraction through laser dissection.

The effort aims to sequence at least 150 animals, plants, and microbes selected for their potential benefits to Canada in the next three years.

The assay correlates shortened telomere lengths in patients of different ages to potential risks for inherited diseases, such as bone marrow failure syndrome and liver cancer.

Genome Canada and its partners recently funded two new initiatives with C$255 that will back precision medicine, genomics, and technology development.

Pages

AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.

According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.

Time magazine looks into how liquid biopsies are changing cancer care.

In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.